ARYL-SUBSTITUTED POLYCYCLIC AMINES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT
First Claim
Patent Images
1. A compound of formula (I):
- wherein;
A, B, D, and G are, independently of one another, N or C(R3);
or, alternatively,groups A and B or groups D and G are, in each case, C(R3) and together form a 5- or 6-membered carbocyclic or heterocyclic radical to result overall in a bicyclic system;
wherein R3 is H, F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, O—
(C1-C6)-alkyl, O—
(C1-C4)-alkoxy-(C1-C4)-alkyl, S—
(C1-C6)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C3-C8)-cycloalkyl, O—
(C3-C8)-cycloalkyl, (C3-C8)-cycloalkenyl, (C2-C6)-alkynyl, (C0-C8)-alkylene-aryl, O—
(C0-C8)-alkylene-aryl, S-aryl, N(R4)(R5), SO2—
CH3, COOH, COO—
(C1-C6)-alkyl, CON(R6)(R7), N(R8)CO(R9), N(R10)SO2(R11), CO(R12), or (CR13R14)x—
O(R15);
wherein R4, R5, R6, R7, R8, R10 are, independently of one another, H or (C1-C8)-alkyl;
or, alternatively, R4 and R5, R6 and R7, independently of one another, taken together with the nitrogen atom to which they are attached form a 5-6 membered ring which optionally may contain an additional heteroatom selected from the group consisting of NH, N—
(C1-C6)-alkyl, oxygen and sulfur;
R9, R11, and R12 are, independently of one another, H, (C1-C8)-alkyl or aryl;
R13 and R14 are, independently of one another, H or (C1-C8)-alkyl;
R15 is H, (C1-C6)-alkyl or aryl;
x is 0, 1, 2, 3, 4, 5 or 6;
R1 is H, (C1-C8)-alkyl, (C3-C6)-alkenyl, or (C3-C6)-alkynyl;
X is N(R16), O, a bond, (R17)C═
C(R18), C≡
C, or a group of the formula (CR19R20)y, in which one or two (CR19R20) groups may be replaced by Y;
Y is O, S, N(R21), or C═
O;
R16, R17, and R18 are, independently of one another, H or (C1-C8)-alkyl;
R19 and R20 are, independently of one another, H or (C1-C4)-alkyl;
y is 1, 2, 3, 4, 5 or 6;
R21 is H or (C1-C8)-alkyl;
E is a 3-14 membered bivalent carbo- or heterocyclic ring structure having 0-4 heteroatoms selected from the group consisting of N, O and S, which ring structure may optionally have substituents selected from the group consisting of H, F, Cl, Br, I, OH, CF3, CN, OCF3, oxo, O—
(C1-C6)-alkyl, O—
(C1-C4)-alkoxy-(C1-C4)-alkyl, S—
(C1-C6)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C3-C8)-cycloalkyl, O—
(C3-C8)-cycloalkyl, (C3-C8)-cycloalkenyl, O—
(C3-C8)-cycloalkenyl, (C2-C6)-alkynyl, (C0-C8)-alkylene-aryl, O—
(C0-C8)-alkylene-aryl, S-aryl, N(R22)(R23), SO2—
CH3, CON(R24)(R25), N(R26)CO(R27), N(R28)SO2(R29), and CO(R30) and may be mono- or bicyclic, wherein E is not a tetrazol-5-yl group;
R22, R23, R24, R25, R26, and R28 are, independently of one another, H, (C1-C8)-alkyl or aryl;
or, alternatively, R22 and R23, R24 and R25, independently of one another, taken together with the nitrogen atom to which they are attached form a 5-6 membered ring which optionally may contain an additional heteroatom selected from the group consisting of NH, N—
(C1-C6)-alkyl, oxygen and sulfur;
R27, R29 and R30 are, independently of one another, H, (C1-C8)-alkyl or aryl;
K is a bond, C≡
C, (R31)C═
C(R32), or a group of the formula (CR33R34)z in which one or more (CR33R34) groups may be replaced by Z;
R31, R32, R35, R36, R37, R38, and R39 are, independently of one another, H or (C1-C8)-alkyl;
Z is O, S, N(R40), CO, SO, or SO2;
R33 and R34 are, independently of one another, H, (C1-C8)-alkyl, hydroxy-(C1-C4)-alkyl, hydroxy, or (C1-C4)-alkoxy-(C1-C4)-alkyl;
z is 1, 2, 3, 4, 5 or 6;
R40 is H or (C1-C8)-alkyl;
R2 is H, (C1-C8)-alkyl, (C1-C8)-alkoxy-(C1-C4)-alkyl, (C3-C8)-alkenyl, (C3-C8)-alkynyl, or a 3 to 10-membered mono-, bi-, tri- or spirocyclic ring which may include 0 to 4 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur, wherein the ring system may additionally be substituted with one or more of the following substituents;
F, Cl, Br, CF3, NO2, CN, (C1-C6)-alkyl, O—
(C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C0-C8)-alkylene-aryl, oxo, CO(R41), CON(R42)(R43), hydroxy, COO(R44), N(R45)CO(C1-C6)-alkyl, N(R46)(R47), SO2CH3, SCF3 and S—
(C1-C6)-alkyl, and wherein R2 is not a tetrazol-5-yl group;
R41, R42, R43, R44, R45, R46, and R47 are, independently of one another, H or (C1-C8)-alkyl;
or, alternatively, R42 and R43, R46 and R47, independently of one another, taken together with the nitrogen atom to which they are attached form a 5-6 membered ring which optionally may contain an additional heteroatom selected from the group consisting of NH, N—
(C1-C6)-alkyl, oxygen and sulfur;
E, K and R2 together form a tricyclic system wherein the rings may be, independently of one another, saturated, partially saturated or unsaturated and, in each case, comprise 3-8 ring atoms;
L is a (CR48R49)m group in which one or more (CR48R49) groups may be replaced by M, provided that L is M if Q is wherein R91 is as defined below;
M is O;
m is 1, 2, 3, 4, 5, or 6, R48 and R49 are, independently of one another, H, (C1-C6)-alkyl, or aryl;
Q is selected from the following structures;
R91 is H, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, CO(R92), (CR93R94)O′
-R95, or CO(CR93R94)p′
-R96;
R92 is H or (C1-C8)-alkyl;
R93 and R94 are, independently of one another, H, (C1-C8)-alkyl, OH, (C3-C8)-cycloalkyl, or (C1-C4)-alkoxy-(C1-C4)-alkyl;
o′ and
p′
are, independently of one another, 0, 1, 2, 3, 4, 5 or 6;
R95 and R96 are, independently of one another, OH, O—
(C1-C8)-alkyl, CON(R97)(R98), N(R99)CO(R100), N(R101)(R102), CO2(R103), SO2Me, CN, or a 3-10 membered ring system having 0 to 3 heteroatoms selected from the group consisting of N, O and S, and which may be substituted with one or more of the following substituents;
F, Cl, Br, CF3, (C1-C8)-alkyl, O—
(C1-C8)-alkyl, CO(R104), oxo, and OH;
R97, R98, R99, R100, R103, and R104 are, independently of one another, H or (C1-C8)-alkyl;
or, alternatively, R97 and R98 taken together with the nitrogen atom to which they are attached form a 5-6 membered ring which optionally may contain an additional heteroatom selected from the group consisting of NH, N—
(C1-C6)-alkyl, oxygen and sulfur;
R101 and R102 are, independently of one another, H, (C1-C6)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, CO(R105), (CR106R107)q′
-R108, or CO(CR109R110)r′
-R111;
or, alternatively, R101 and R102 form, together with the nitrogen atom to which they are bonded, a 4 to 10-membered mono-, bi- or spirocyclic ring which, apart from the nitrogen atom, comprises 0 to 3 additional heteroatoms selected from the group consisting of N, O and S and which ring may additionally be substituted with one or more of the following substituents;
F, Cl, Br, CF3, O—
(C1-C8)-alkyl, (C1-C6)-alkyl, CO(R112), oxo, OH, (C1-C4)-alkoxy-(C1-C4)-alkyl, hydroxy-(C1-C4)-alkyl, CON(R113)(R114), N(R115)CO(R116), N(R117)(R118), CO2(R119), and SO2Me;
R105, R106, R107, R108, R109, R10, R112, R113, R114, R115, R116, R117, R118, and R119 are, independently of one another, H or (C1-C8)-alkyl;
or, alternatively, R117 and R118 taken together with the nitrogen atom to which they are attached form a 5-6 membered ring which optionally may contain an additional heteroatom selected from the group consisting of NH, N—
(C1-C6)-alkyl, oxygen and sulfur;
q′ and
r′
are, independently of one another, 0, 1, 2, 3, 4, 5 or 6;
R108 and R111 are, independently of one another, OH, O—
(C1-C8)-alkyl, CON(R120)(R121), N(R122)CO(R123), N(R124)(R125), CO2(R126), SO2Me, CN, or a 3-10 membered ring system having 0 to 3 heteroatoms selected from the group consisting of N, O and S, which ring system may be substituted with one or more of the following substituents;
F, Cl, Br, CF3, (C1-C8)-alkyl, O—
(C1-C8)-alkyl, CO(R127), oxo, and OH;
R120, R121, R122, R123, R124, R125, R126, and R127 are, independently of one another, H or (C1-C8)-alkyl;
or, alternatively, R120 and R121, R124 and R125, independently of one another, taken together with the nitrogen atom to which they are attached form a 5-6 membered ring which optionally may contain an additional heteroatom selected from the group consisting of NH, N—
(C1-C6)-alkyl, oxygen and sulfur;
or an N-oxide thereof or a physiologically tolerated salt thereof.
1 Assignment
0 Petitions
Accused Products
Abstract
The invention relates to aryl-substituted polycyclic amines of the formula I, especially bicyclic amines, and to the physiologically tolerated salts and physiologically functional derivatives thereof;
where the symbols and radicals are explained in the description as well as to pharmaceutical compositions and medical treatments employing these compounds.
4 Citations
24 Claims
-
1. A compound of formula (I):
-
wherein; A, B, D, and G are, independently of one another, N or C(R3); or, alternatively, groups A and B or groups D and G are, in each case, C(R3) and together form a 5- or 6-membered carbocyclic or heterocyclic radical to result overall in a bicyclic system;
whereinR3 is H, F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, O—
(C1-C6)-alkyl, O—
(C1-C4)-alkoxy-(C1-C4)-alkyl, S—
(C1-C6)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C3-C8)-cycloalkyl, O—
(C3-C8)-cycloalkyl, (C3-C8)-cycloalkenyl, (C2-C6)-alkynyl, (C0-C8)-alkylene-aryl, O—
(C0-C8)-alkylene-aryl, S-aryl, N(R4)(R5), SO2—
CH3, COOH, COO—
(C1-C6)-alkyl, CON(R6)(R7), N(R8)CO(R9), N(R10)SO2(R11), CO(R12), or (CR13R14)x—
O(R15);
whereinR4, R5, R6, R7, R8, R10 are, independently of one another, H or (C1-C8)-alkyl; or, alternatively, R4 and R5, R6 and R7, independently of one another, taken together with the nitrogen atom to which they are attached form a 5-6 membered ring which optionally may contain an additional heteroatom selected from the group consisting of NH, N—
(C1-C6)-alkyl, oxygen and sulfur;R9, R11, and R12 are, independently of one another, H, (C1-C8)-alkyl or aryl; R13 and R14 are, independently of one another, H or (C1-C8)-alkyl; R15 is H, (C1-C6)-alkyl or aryl; x is 0, 1, 2, 3, 4, 5 or 6; R1 is H, (C1-C8)-alkyl, (C3-C6)-alkenyl, or (C3-C6)-alkynyl; X is N(R16), O, a bond, (R17)C═
C(R18), C≡
C, or a group of the formula (CR19R20)y, in which one or two (CR19R20) groups may be replaced by Y;Y is O, S, N(R21), or C═
O;R16, R17, and R18 are, independently of one another, H or (C1-C8)-alkyl; R19 and R20 are, independently of one another, H or (C1-C4)-alkyl; y is 1, 2, 3, 4, 5 or 6; R21 is H or (C1-C8)-alkyl; E is a 3-14 membered bivalent carbo- or heterocyclic ring structure having 0-4 heteroatoms selected from the group consisting of N, O and S, which ring structure may optionally have substituents selected from the group consisting of H, F, Cl, Br, I, OH, CF3, CN, OCF3, oxo, O—
(C1-C6)-alkyl, O—
(C1-C4)-alkoxy-(C1-C4)-alkyl, S—
(C1-C6)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C3-C8)-cycloalkyl, O—
(C3-C8)-cycloalkyl, (C3-C8)-cycloalkenyl, O—
(C3-C8)-cycloalkenyl, (C2-C6)-alkynyl, (C0-C8)-alkylene-aryl, O—
(C0-C8)-alkylene-aryl, S-aryl, N(R22)(R23), SO2—
CH3, CON(R24)(R25), N(R26)CO(R27), N(R28)SO2(R29), and CO(R30) and may be mono- or bicyclic, wherein E is not a tetrazol-5-yl group;R22, R23, R24, R25, R26, and R28 are, independently of one another, H, (C1-C8)-alkyl or aryl; or, alternatively, R22 and R23, R24 and R25, independently of one another, taken together with the nitrogen atom to which they are attached form a 5-6 membered ring which optionally may contain an additional heteroatom selected from the group consisting of NH, N—
(C1-C6)-alkyl, oxygen and sulfur;R27, R29 and R30 are, independently of one another, H, (C1-C8)-alkyl or aryl; K is a bond, C≡
C, (R31)C═
C(R32), or a group of the formula (CR33R34)z in which one or more (CR33R34) groups may be replaced by Z;R31, R32, R35, R36, R37, R38, and R39 are, independently of one another, H or (C1-C8)-alkyl; Z is O, S, N(R40), CO, SO, or SO2; R33 and R34 are, independently of one another, H, (C1-C8)-alkyl, hydroxy-(C1-C4)-alkyl, hydroxy, or (C1-C4)-alkoxy-(C1-C4)-alkyl; z is 1, 2, 3, 4, 5 or 6; R40 is H or (C1-C8)-alkyl; R2 is H, (C1-C8)-alkyl, (C1-C8)-alkoxy-(C1-C4)-alkyl, (C3-C8)-alkenyl, (C3-C8)-alkynyl, or a 3 to 10-membered mono-, bi-, tri- or spirocyclic ring which may include 0 to 4 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur, wherein the ring system may additionally be substituted with one or more of the following substituents;
F, Cl, Br, CF3, NO2, CN, (C1-C6)-alkyl, O—
(C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C0-C8)-alkylene-aryl, oxo, CO(R41), CON(R42)(R43), hydroxy, COO(R44), N(R45)CO(C1-C6)-alkyl, N(R46)(R47), SO2CH3, SCF3 and S—
(C1-C6)-alkyl, and wherein R2 is not a tetrazol-5-yl group;R41, R42, R43, R44, R45, R46, and R47 are, independently of one another, H or (C1-C8)-alkyl; or, alternatively, R42 and R43, R46 and R47, independently of one another, taken together with the nitrogen atom to which they are attached form a 5-6 membered ring which optionally may contain an additional heteroatom selected from the group consisting of NH, N—
(C1-C6)-alkyl, oxygen and sulfur;E, K and R2 together form a tricyclic system wherein the rings may be, independently of one another, saturated, partially saturated or unsaturated and, in each case, comprise 3-8 ring atoms; L is a (CR48R49)m group in which one or more (CR48R49) groups may be replaced by M, provided that L is M if Q is wherein R91 is as defined below; M is O; m is 1, 2, 3, 4, 5, or 6, R48 and R49 are, independently of one another, H, (C1-C6)-alkyl, or aryl; Q is selected from the following structures; R91 is H, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, CO(R92), (CR93R94)O′
-R95, or CO(CR93R94)p′
-R96;R92 is H or (C1-C8)-alkyl; R93 and R94 are, independently of one another, H, (C1-C8)-alkyl, OH, (C3-C8)-cycloalkyl, or (C1-C4)-alkoxy-(C1-C4)-alkyl; o′ and
p′
are, independently of one another, 0, 1, 2, 3, 4, 5 or 6;R95 and R96 are, independently of one another, OH, O—
(C1-C8)-alkyl, CON(R97)(R98), N(R99)CO(R100), N(R101)(R102), CO2(R103), SO2Me, CN, or a 3-10 membered ring system having 0 to 3 heteroatoms selected from the group consisting of N, O and S, and which may be substituted with one or more of the following substituents;
F, Cl, Br, CF3, (C1-C8)-alkyl, O—
(C1-C8)-alkyl, CO(R104), oxo, and OH;R97, R98, R99, R100, R103, and R104 are, independently of one another, H or (C1-C8)-alkyl; or, alternatively, R97 and R98 taken together with the nitrogen atom to which they are attached form a 5-6 membered ring which optionally may contain an additional heteroatom selected from the group consisting of NH, N—
(C1-C6)-alkyl, oxygen and sulfur;R101 and R102 are, independently of one another, H, (C1-C6)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, CO(R105), (CR106R107)q′
-R108, or CO(CR109R110)r′
-R111;
or, alternatively, R101 and R102 form, together with the nitrogen atom to which they are bonded, a 4 to 10-membered mono-, bi- or spirocyclic ring which, apart from the nitrogen atom, comprises 0 to 3 additional heteroatoms selected from the group consisting of N, O and S and which ring may additionally be substituted with one or more of the following substituents;
F, Cl, Br, CF3, O—
(C1-C8)-alkyl, (C1-C6)-alkyl, CO(R112), oxo, OH, (C1-C4)-alkoxy-(C1-C4)-alkyl, hydroxy-(C1-C4)-alkyl, CON(R113)(R114), N(R115)CO(R116), N(R117)(R118), CO2(R119), and SO2Me;R105, R106, R107, R108, R109, R10, R112, R113, R114, R115, R116, R117, R118, and R119 are, independently of one another, H or (C1-C8)-alkyl; or, alternatively, R117 and R118 taken together with the nitrogen atom to which they are attached form a 5-6 membered ring which optionally may contain an additional heteroatom selected from the group consisting of NH, N—
(C1-C6)-alkyl, oxygen and sulfur;q′ and
r′
are, independently of one another, 0, 1, 2, 3, 4, 5 or 6;R108 and R111 are, independently of one another, OH, O—
(C1-C8)-alkyl, CON(R120)(R121), N(R122)CO(R123), N(R124)(R125), CO2(R126), SO2Me, CN, or a 3-10 membered ring system having 0 to 3 heteroatoms selected from the group consisting of N, O and S, which ring system may be substituted with one or more of the following substituents;
F, Cl, Br, CF3, (C1-C8)-alkyl, O—
(C1-C8)-alkyl, CO(R127), oxo, and OH;R120, R121, R122, R123, R124, R125, R126, and R127 are, independently of one another, H or (C1-C8)-alkyl; or, alternatively, R120 and R121, R124 and R125, independently of one another, taken together with the nitrogen atom to which they are attached form a 5-6 membered ring which optionally may contain an additional heteroatom selected from the group consisting of NH, N—
(C1-C6)-alkyl, oxygen and sulfur;or an N-oxide thereof or a physiologically tolerated salt thereof. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)
m is 1, 2, 3 or 4; R48 and R49 are each H; Q is selected from; R91 is H, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, CO(R92), (CR93R94)O′
-R95, or CO(CR93R94)p′
-R96;R92 is H or (C1-C8)-alkyl; R93 and R94 are, independently of one another, H, (C1-C8)-alkyl, OH, (C3-C8)-cycloalkyl, or (C1-C4)-alkoxy-(C1-C4)alkyl; o′ and
p′
are, independently of one another, 0, 1, 2, 3, 4, 5 or 6,R95 and R96 are, independently of one another, OH, O—
(C1-C8)-alkyl, CON(R97)(R98), N(R99)CO(R100), N(R101)(R102), CO2(R103), SO2Me, CN, or a 3-10 membered ring system having 0 to 3 heteroatoms selected from the group consisting of N, O and S, which ring system may be substituted with one or more of the following substituents;
F, Cl, Br, CF3, (C1-C8)-alkyl, O—
(C1-C8)-alkyl, CO(R104), oxo, and OH;R97, R98, R99, R100, R103 and R104 are, independently of one another, H or (C1-C8)-alkyl; or, alternatively, R97 and R98 taken together with the nitrogen atom to which they are attached form a 5-6 membered ring which optionally may contain an additional heteroatom selected from the group consisting of NH, N—
(C1-C6)-alkyl, oxygen and sulfur;R101 and R102 are, independently of one another, H, (C1-C6)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, CO(R105), (CR106R107)q′
-R108, or CO(CR109R110)r′
-R111;
or, alternatively, R101 and R102 form, together with the nitrogen atom to which they are bonded, a 4 to 10-membered mono-, bi- or spirocyclic ring which, apart from the nitrogen atom, comprises 0 to 3 additional heteroatoms selected from the group consisting of N, O and S and may additionally be substituted with one or more of the following substituents;
F, Cl, Br, CF3, O—
(C1-C8)-alkyl, (C1-C6)-alkyl, CO(R112), oxo, OH, (C1-C4)-alkoxy-(C1-C4)-alkyl, hydroxy-(C1-C4)-alkyl, CON(R113)(R114), N(R115)CO(R116), N(R117)(R118), CO2(R119), and SO2Me;R105, R106, R107, R108, R109, R110, R112, R113, R114, R115, R116, R117, R118 and R119 are, independently of one another, H or (C1-C8)-alkyl; or, alternatively, R117 and R118 taken together with the nitrogen atom to which they are attached form a 5-6 membered ring which optionally may contain an additional heteroatom selected from the group consisting of NH, N—
(C1-C6)-alkyl, oxygen and sulfur;q′ and
r′
are, independently of one another, 0, 1, 2, 3, 4, 5 or 6;R108 and R111 are, independently of one another, OH, O—
(C1-C8)-alkyl, CON(R120)(R121), N(R122)CO(R123), N(R124)(R125), CO2(R126), SO2Me, CN, or a 3-10 membered ring system having 0 to 3 heteroatoms selected from the group consisting of N, O and S, which ring system may be substituted with one or more of the following substituents;
F, Cl, Br, CF3, (C1-C8)-alkyl, O—
(C1-C8)-alkyl, CO(R127), oxo, and OH;R120, R121, R122, R123, R124, R125, R126 and R127 are, independently of one another, H or (C1-C8)-alkyl; or, alternatively, R120 and R121, R124 and R125, independently of one another, taken together with the nitrogen atom to which they are attached form a 5-6 membered ring which optionally may contain an additional heteroatom selected from the group consisting of NH, N—
(C1-C6)-alkyl, oxygen and sulfur;or an N-oxide thereof or a physiologically tolerated salt thereof.
-
-
4. The compound according to claim 3, wherein Q is selected from:
R91 is H, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, CO(R92), (CR93R94)o′
-R95, or CO(CR93R94)p′
-R96;R92 is H or (C1-C8)-alkyl; R93 and R94 are, independently of one another, H, (C1-C8)-alkyl, OH, (C3-C8)-cycloalkyl, or (C1-C4)-alkoxy-(C1-C4)alkyl; o′ and
p′
are, independently of one another, 0, 1, 2, 3, 4, 5 or 6;R95 and R96 are, independently of one another, OH, O—
(C1-C8)-alkyl, CON(R97)(R98), N(R99)CO(R100), N(R111)(R102), CO2(R103), SO2Me, CN, or a 3-10 membered ring system having 0 to 3 heteroatoms selected from the group consisting of N, O and S, which ring system may be substituted by one or more of the following substituents;
F, Cl, Br, CF3, (C1-C8)-alkyl, O—
(C1-C8)-alkyl, CO(R104), oxo, and OH;R97, R98, R99, R100, R103 and R104 are, independently of one another, H or (C1-C8)-alkyl; or, alternatively, R97 and R98 taken together with the nitrogen atom to which they are attached form a 5-6 membered ring which optionally may contain an additional heteroatom selected from the group consisting of NH, N—
(C1-C6)-alkyl, oxygen and sulfur;R101 and R102 are, independently of one another, H, (C1-C6)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, CO(R105), (CR106R107)q′
-R108, or CO(CR109R110)r′
-R111;
or, alternatively, R101 and R102 form, together with the nitrogen atom to which they are bonded, a 4 to 10-membered mono-, bi- or spirocyclic ring which, apart from the nitrogen atom, comprises 0 to 3 additional heteroatoms selected from the group consisting of N, O and S and may additionally be substituted with one or more of the following substituents;
F, Cl, Br, CF3, O—
(C1-C8)-alkyl, (C1-C6)-alkyl, CO(R112), oxo, OH, (C1-C4)-alkoxy-(C1-C4)-alkyl, hydroxy-(C1-C4)-alkyl, CON(R113)(R114), N(R115)CO(R116), N(R117)(R118), CO2(R119), and SO2Me;R105, R106, R107, R108, R109, R110, R112, R113, R114, R115, R116, R117, R118, and R119 are, independently of one another, H or (C1-C8)-alkyl; or, alternatively, R117 and R118 taken together with the nitrogen atom to which they are attached form a 5-6 membered ring which optionally may contain an additional heteroatom selected from the group consisting of NH, N—
(C1-C6)-alkyl, oxygen and sulfur;q′ and
r′
are, independently of one another, 0, 1, 2, 3, 4, 5 or 6;R108 and R111 are, independently of one another, OH, O—
(C1-C8)-alkyl, CON(R120)(R121), N(R122)CO(R123), N(R124)(R125), CO2(R126), SO2Me, CN, or a 3-10 membered ring system having 0 to 3 heteroatoms selected from the group consisting of N, O and S, which ring system may be substituted with one or more of the following substituents;
F, Cl, Br, CF3, (C1-C8)-alkyl, O—
(C1-C8)-alkyl, CO(R127), oxo, and OH;R120, R121, R122, R123, R124, R125, R126, and R127 are, independently of one another, H or (C1-C8)-alkyl; or, alternatively, R120 and R121, R124 and R125, independently of one another, taken together with the nitrogen atom to which they are attached form a 5-6 membered ring which optionally may contain an additional heteroatom selected from the group consisting of NH, N—
(C1-C6)-alkyl, oxygen and sulfur.
-
5. The compound according to claim 4, wherein Q is:
-
6. The compound according to claim 4, wherein Q is:
R91 is H, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, CO(R92), (CR93R94)o′
-R95, or CO(CR93R94)p′
-R96;R92 is H or (C1-C8)-alkyl; R93 and R94 are, independently of one another, H, (C1-C8)-alkyl, OH, (C3-C8)-cycloalkyl, or (C1-C4)-alkoxy-(C1-C4)alkyl; o′ and
p′
are, independently of one another, 0, 1, 2, 3, 4, 5 or 6;R95 and R96 are, independently of one another, OH, O—
(C1-C8)-alkyl, CON(R97)(R98), N(R99)CO(R100), N(R111)(R102), CO2(R103), SO2Me, CN, or a 3-10 membered ring system having 0 to 3 heteroatoms selected from the group consisting of N, O and S, which ring system may be substituted with one or more of the following substituents;
F, Cl, Br, CF3, (C1-C8)-alkyl, O—
(C1-C8)-alkyl, CO(R104), oxo, and OH;R97, R98, R99, R100, R103, and R104 are, independently of one another, H or (C1-C8)-alkyl; or, alternatively, R97 and R98 taken together with the nitrogen atom to which they are attached form a 5-6 membered ring which optionally may contain an additional heteroatom selected from the group consisting of NH, N—
(C1-C6)-alkyl, oxygen and sulfur;R101, and R102 are, independently of one another H, (C1-C6)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, CO(R105), (CR106R107)q′
-R108, or CO(CR109R110)r′
-R111;
or, alternatively, R101 and R102 form, together with the nitrogen atom to which they are bonded, a 4 to 10-membered mono-, bi- or spirocyclic ring which, apart from the nitrogen atom, comprises 0 to 3 additional heteroatoms selected from the group consisting of N, O and S and may additionally be substituted with one or more of the following substituents;
F, Cl, Br, CF3, O—
(C1-C8)-alkyl, (C1-C6)-alkyl, CO(R112), oxo, OH, (C1-C4)-alkoxy-(C1-C4)-alkyl, hydroxy-(C1-C4)-alkyl, CON(R113)(R114), N(R115)CO(R116), N(R117)(R118), CO2(R119), and SO2Me;R105, R106, R107, R108, R109, R110, R112, R113, R114, R115, R116, R117, R118, and R119 are, independently of one another, H or (C1-C8)-alkyl; or, alternatively, R117 and R118 taken together with the nitrogen atom to which they are attached form a 5-6 membered ring which optionally may contain an additional heteroatom selected from the group consisting of NH, N—
(C1-C6)-alkyl, oxygen and sulfur;q′ and
r′
are, independently of one another, 0, 1, 2, 3, 4, 5 or 6;R108 and R111 are, independently of one another, OH, O—
(C1-C8)-alkyl, CON(R120)(R121), N(R122)CO(R123), N(R124)(R125), CO2(R126), SO2Me, CN, or a 3-10 membered ring system having 0 to 3 heteroatoms selected from the group consisting of N, O and S, which ring system may be substituted with one or more of the following substituents;
F, Cl, Br, CF3, (C1-C8)-alkyl, O—
(C1-C8)-alkyl, CO(R127), oxo, and OH;R120, R121, R122, R123, R124, R125, R126, and R127 are, independently of one another, H or (C1-C8)-alkyl; or, alternatively, R120 and R121, R124 and R125, independently of one another, taken together with the nitrogen atom to which they are attached form a 5-6 membered ring which optionally may contain an additional heteroatom selected from the group consisting of NH, N—
(C1-C6)-alkyl, oxygen and sulfur; andL is O.
-
7. The compound according to claim 1, wherein L is selected from O and CH2O, L being O if Q is
-
8. The compound according to claim 7, wherein the group L-Q is:
R91 is H, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, CO(R92), (CR93R94)o′
-R95, or CO(CR93R94)p′
-R96;R92 is H or (C1-C8)-alkyl; R93 and R94 are, independently of one another, H, (C1-C8)-alkyl, OH, (C3-C8)-cycloalkyl, or (C1-C4)-alkoxy-(C1-C4)alkyl; o′ and
p′
are, independently of one another, 0, 1, 2, 3, 4, 5 or 6;R95 and R96 are, independently of one another, OH, O—
(C1-C8)-alkyl, CON(R97)(R98), N(R99)CO(R100), N(R111)(R102), CO2(R103), SO2Me, CN, or a 3-10 membered ring system having 0 to 3 heteroatoms selected from the group consisting of N, O and S, which ring system may be substituted with one or more of the following substituents;
F, Cl, Br, CF3, (C1-C8)-alkyl, O—
(C1-C8)-alkyl, CO(R104), oxo, and OH;R97, R98, R99, R100, R103, and R104 are, independently of one another, H or (C1-C8)-alkyl; or, alternatively, R97 and R98 taken together with the nitrogen atom to which they are attached form a 5-6 membered ring which optionally may contain an additional heteroatom selected from the group consisting of NH, N—
(C1-C6)-alkyl, oxygen and sulfur;R101 and R102 are, independently of one another, H, (C1-C6)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, CO(R105), (CR106R107)q′
-R108, or CO(CR109R110)r′
-R111;
or, alternatively, R101 and R102 form, together with the nitrogen atom to which they are bonded, a 4 to 10-membered mono-, bi- or spirocyclic ring which, apart from the nitrogen atom, comprises 0 to 3 additional heteroatoms selected from the group consisting of N, O and S and may additionally be substituted with one or more of the following substituents;
F, Cl, Br, CF3, O—
(C1-C8)-alkyl, (C1-C6)-alkyl, CO(R112), oxo, OH, (C1-C4)-alkoxy-(C1-C4)-alkyl, hydroxy-(C1-C4)-alkyl, CON(R113)(R114), N(R115)CO(R116), N(R117)(R118), CO2(R119), and SO2Me;R105, R106, R107, R108, R109, R110, R112, R113, R114, R115, R116, R117, R118, and R119 are, independently of one another, H or (C1-C8)-alkyl; or, alternatively, R117 and R118 taken together with the nitrogen atom to which they are attached form a 5-6 membered ring which optionally may contain an additional heteroatom selected from the group consisting of NH, N—
(C1-C6)-alkyl, oxygen and sulfur;q′ and
r′
are, independently of one another, 0, 1, 2, 3, 4, 5 or 6;R108 and R111 are, independently of one another, OH, O—
(C1-C8)-alkyl, CON(R120)(R121), N(R122)CO(R123), N(R124)(R125), CO2(R126), SO2Me, CN, or a 3-10 membered ring system having 0 to 3 heteroatoms selected from the group consisting of N, O and S, which ring system may be substituted with one or more of the following substituents;
F, Cl, Br, CF3, (C1-C8)-alkyl, O—
(C1-C8)-alkyl, CO(R127), oxo, and OH;R120, R121, R122, R123, R124, R125, R126, and R127 are, independently of one another, H or (C1-C8)-alkyl; or, alternatively, R120 and R121, R124 and R125, independently of one another, taken together with the nitrogen atom to which they are attached form a 5-6 membered ring which optionally may contain an additional heteroatom selected from the group consisting of NH, N—
(C1-C6)-alkyl, oxygen and sulfur.
-
9. The compound according to claim 1, wherein:
A, B, D, and G are, independently of one another, N or C(R3), and the total number of nitrogen atoms in this ring is 0-2.
-
10. The compound according to claim 1, wherein:
-
K is O, OCH2, CH2O, S, SO, SO2, N(R35), N(R36)CO, CON(R37), (C(R38)(R39))v, CO, (R31)C═
C(R32), C≡
C, SCH2, SO2CH2, preferably OCH2, CH2O, N(R36)CO, CON(R37), (C(R38)(R39))2, (R31)C═
C(R32), C≡
C, SCH2, SO2CH2, particularly preferably OCH2, CH2O, CON(R37), C≡
C, or SCH2;
whereinv is 1, 2 or 3; and R31, R32, R35, R36, R37, R38, and R39 are, independently of one another, H or (C1-C8)-alkyl.
-
-
11. The compound according to claim 1, wherein:
-
A, B, D, and G are, independently of each other, C(R3);
whereinR3 is H, F, Cl, Br, CF3, CN, O—
(C1-C6)-alkyl, O—
(C1-C4)-alkoxy-(C1-C4)-alkyl, S—
(C1-C6)-alkyl, (C1-C6)-alkyl, (C0-C8)-alkylene-aryl, O—
(C0-C8)-alkylene-aryl, N(R4)(R5), SO2—
CH3, CON(R6)(R7), N(R8)CO(R9), CO(R12), or (CR13R14)x—
O(R15);R4, R5, R6, R7, and R8 are, independently of one another, H or (C1-C8)-alkyl; or, alternatively, R4 and R5, R6 and R7 form, independently of one another, together with the nitrogen atom to which they are bonded, a 5-6 membered ring which optionally may contain an additional heteroatom selected from the group consisting of NH, N—
(C1-C6)-alkyl, oxygen and sulfur;R9 and R12 are, independently of one another, H or (C1-C8)-alkyl; R13 and R14 are each H; R15 is H or (C1-C6)-alkyl; and x is 0, 1 or 2.
-
-
12. The compound according to claim 1, wherein X is a bond or N(R16), in which R16 is H or (C1-C8)-alkyl.
-
13. A pharmaceutical composition comprising one or more compounds according to claim 1 or a physiologically acceptable salt thereof in combination with at least one pharmaceutically acceptable excipient.
-
14. A pharmaceutical composition comprising one or more compounds according to claim 2 or a physiologically acceptable salt thereof in combination with at least one pharmaceutically acceptable excipient.
-
15. A pharmaceutical composition comprising one or more compounds according to claim 3 or a physiologically acceptable salt thereof in combination with at least one pharmaceutically acceptable excipient.
-
16. A pharmaceutical composition comprising one or more compounds according to claim 4 or a physiologically acceptable salt thereof in combination with at least one pharmaceutically acceptable excipient.
-
17. A pharmaceutical composition comprising one or more compounds according to claim 5 or a physiologically acceptable salt thereof in combination with at least one pharmaceutically acceptable excipient.
-
18. A pharmaceutical composition comprising one or more compounds according to claim 6 or a physiologically acceptable salt thereof in combination with at least one pharmaceutically acceptable excipient.
-
19. A method for the treatment of obesity which comprises administering to a patient in need of said treatment an effective amount of a compound of claim 1 or a physiologically acceptable salt thereof.
-
20. A method for the treatment of obesity which comprises administering to a patient in need of said treatment an effective amount of a compound of claim 2 or a physiologically acceptable salt thereof.
-
21. A method for the treatment of obesity which comprises administering to a patient in need of said treatment an effective amount of a compound of claim 3 or a physiologically acceptable salt thereof.
-
22. A method for the treatment of obesity which comprises administering to a patient in need of said treatment an effective amount of a compound of claim 4 or a physiologically acceptable salt thereof.
-
23. A method for the treatment of obesity which comprises administering to a patient in need of said treatment an effective amount of a compound of claim 5 or a physiologically acceptable salt thereof.
-
24. A method for the treatment of obesity which comprises administering to a patient in need of said treatment an effective amount of a compound of claim 6 or a physiologically acceptable salt thereof.
Specification